Search
patiromer (Veltassa)
Indications:
- hyperkalemia (FDA-approved Oct 2015)
- useful in patients with chronic renal failure on ACE inhibitors, ARBs or other RAAS Inhibitor (spironolactone)
Contraindications:
- not appropriate for rapid correction of severe hyperkalemia [2]
Adverse effects:
- constipation
- diarrhea
- nausea
- abdominal discomfort
- flatulence
- hypomagnesemia [2]
Mechanism of action:
- nonabsorbed polymer that binds K+ in the GI tract
General
metabolic agent (metabolic modifier)
gastrointestinal agent
polymer
References
- Weir MR et al
Patiromer in Patients with Kidney Disease and Hyperkalemia
Receiving RAAS Inhibitors.
N Engl J Med. Nov 21, 2014
PMID: 25415805
http://www.nejm.org/doi/full/10.1056/NEJMoa1410853
- Ingelfinger JR
A New Era for the Treatment of Hyperkalemia?
N Engl J Med. Nov 21, 2014
PMID: 25415806
http://www.nejm.org/doi/full/10.1056/NEJMe1414112
- Stiles S
FDA Approves Potassium-Binder Patiromer (Veltassa), New Option
for Patients on RAAS Inhibitor-Treated Patients
Medscape Oncology. October 21, 2015
http://www.medscape.com/viewarticle/853049
- FDA News Release. October 21, 2015
FDA approves new drug to treat hyperkalemia
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468546.htm
- Lou N
Patiromer Helps CKD Patients Stay on Spironolactone
- Now the question is: Can outcomes can be improved?
MedPage Today. September 15, 2019
https://www.medpagetoday.com/cardiology/hypertension/82166
- Agarwal R, Rossignol P, Romero A et al
Patiromer versus placebo to enable spironolactone use in patients
with resistant hypertension and chronic kidney disease (AMBER):
A phase 2, randomised, double-blind, placebo-controlled trial.
Lancet 2019. Sept 15
PMID: 31533906
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32135-X/fulltext
- Agarwal R, Rossignol P, Garza D et a;
Patiromer to Enable Spironolactone Use in the Treatment of Patients
with Resistant Hypertension and Chronic Kidney Disease: Rationale
and Design of the AMBER Study.
Am J Nephrol. 2018;48(3):172-180.
PMID: 30176673 Free PMC Article
- Di Palo K, Sinnett MJ, Goriacko P
Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting.
JAMA Netw Open. 2022;5(1):e2145236
PMID: 35080601 Free article
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788445